What Khloé Kardashian has actually said about peptides
Here is the verbatim answer. In an ELLE interview by Katie Berohn published on 5 November 2025, framed as a round of the game F/M/K, Khloé Kardashian chose to marry peptides and explained why: "I cannot see my life without peptides. I take a daily peptide injection, and it has changed my life." That is the whole of her on-record statement about injections. Every roundup since has quoted it, usually with a confident guess about what is in the syringe. The guess is never hers.
Notice what the sentence does not contain. No compound, no dose, no purpose, no prescriber, no hint of whether it came from a pharmacy or a research-use-only vial. Peptide is a chemistry word for a short chain of amino acids, and it covers everything from an FDA-approved diabetes drug to a powder sold online with no human data. Anyone asking what peptides Khloé Kardashian is using deserves the honest first answer: she has never said.
The one product she has named is not an injection. According to NewBeauty, she takes OMI Hair Growth Peptides, a gummy, every morning, and in an Instagram video in August 2025 she said she had been taking them for "months, if not a year". So the public record holds exactly two items, an unnamed daily injectable and a named oral gummy. They share a word and almost nothing else.
What a daily peptide injection means in today's market
We can decode the phrase without pretending to decode the person. The injected peptide market has sorted itself by schedule. Weekly is the rhythm of the acylated GLP-1 drugs and of albumin-bound CJC-1295; daily belongs to compounds whose half-lives run to minutes or hours. When someone on the Beverly Hills longevity circuit says my daily peptide, the phrase usually refers to the growth hormone secretagogues ipamorelin and CJC-1295 without DAC, typically paired; BPC-157, sold for gut and tissue repair; and liraglutide, the once-daily GLP-1 that preceded semaglutide. GHK-Cu, the copper peptide, has joined the list as clinics moved it from creams into syringes, a trend NPR described in September 2026 as running ahead of the science.
None of that is a claim about Khloé Kardashian. She may take one of these, something not on the list, or a compounded blend nobody outside the clinic could name. What we can do is set out what each compound is, what has been measured in humans, and where each stands with the FDA as of September 2026. Every option shares one thing: a daily subcutaneous injection means drawing up and administering a drug product every day, and whether it was made under a manufacturing quality system or arrived from a grey-market website is invisible in any interview quote.
Ipamorelin and CJC-1295: the nightly growth hormone shot
This pairing is the most common answer to daily peptide in the anti-ageing market. Neither contains growth hormone. Ipamorelin is a ghrelin-receptor agonist that tells pituitary somatotrophs to release more of the GH they already hold; its 1998 characterisation in rats and pigs showed GH release with essentially no cortisol or prolactin spill-over. CJC-1295 is a modified fragment of growth hormone releasing hormone; the version sold as without DAC clears in about half an hour, the albumin-bound version lasts days, and the two behave nothing alike.
What has been measured in people is thin. Ipamorelin reached phase 2 for post-operative ileus and was discontinued. CJC-1295 with DAC has phase 1 pharmacokinetics showing GH and IGF-1 elevated for over a week after one dose; no efficacy trial exists for it, for ipamorelin, or for the pairing clinics sell. The nearest verdict on the class is a two-year randomised trial of the oral secretagogue MK-677 in healthy older adults: IGF-1 rose to young-adult levels, fat-free mass rose by roughly 1.6 kg over placebo, strength and function did not improve, and fasting glucose and insulin resistance worsened. That last finding is the class's signature side effect; fluid retention, joint pain, raised appetite and an open question over IGF-1 and cancer risk follow from the same mechanism.
Regulatory status is not ambiguous. Neither compound is approved anywhere. In September 2023 the FDA placed both, alongside BPC-157, GHK-Cu and fifteen other substances, in the 503A bulk-substance category reserved for significant safety risk, removing them from lawful pharmacy compounding. Neither was among the compounds the FDA's advisory committee voted on in July 2026. A clinic offering them today is dispensing neither an approved nor a lawfully compounded drug, and both are prohibited in sport at all times.
BPC-157: the daily healing peptide and its 2026 moment
BPC-157 is a fifteen-amino-acid synthetic peptide described as a fragment of a protein found in gastric juice. It is the most discussed research peptide in the world, taken daily largely because nobody has published a human half-life that would argue for anything else. Its reputation rests on well over a hundred rodent studies reporting faster healing of tendons, muscle, ligaments, bone and gut lesions, concentrated in one Zagreb-based research group and mostly reported without the blinding and randomisation that would let an outsider weigh them.
The human record, stated plainly: as of 2026 there is no published randomised controlled trial of BPC-157 in humans for any indication. What exists is a handful of small uncontrolled pilot studies from a single US group, including a 2025 intravenous safety pilot in a couple of healthy adults, and an oral programme for inflammatory bowel disease two decades ago whose efficacy results were never published. Anyone telling a reader that BPC-157 is clinically proven to heal a tendon is describing rats.
The regulatory story moved in 2026. September 2023: Category 2, barred from compounding. February 2026: Robert F. Kennedy Jr, the Health and Human Services Secretary, promised on Joe Rogan's podcast to restore access and said "we created the gray market". 15 April 2026: the FDA moved twelve peptides out of Category 2, into a limbo pending advisory review rather than into Category 1. 23 and 24 July 2026: the Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, for BPC-157 in ulcerative colitis, even as FDA scientists said they lacked evidence to assess safety or effectiveness. The vote is non-binding; Category 1 placement needs notice-and-comment rulemaking, realistically eight to twelve months, into 2027. BPC-157 remains an unapproved drug sold under research-use-only labelling, with one narrow advisory nod and no human efficacy trial.
The daily GLP-1, and what she has said about Ozempic
There is one class where daily peptide injection describes an FDA-approved medicine with a label and outcome trials behind it. Liraglutide, approved in 2010 for type 2 diabetes and in 2014 for chronic weight management, is a once-daily GLP-1 receptor agonist with roughly a one-day half-life against semaglutide's week. In the 56-week SCALE trial, at its labelled 3 mg daily dose, it produced about 8 per cent weight loss against roughly 2.6 per cent on placebo; the LEADER trial showed a 13 per cent relative reduction in major cardiovascular events in type 2 diabetes. Generics now exist.
Semaglutide is the weekly member of the family, approved for diabetes in 2017 and weight management in 2021: about 15 per cent weight loss over 68 weeks in STEP 1, a 20 per cent relative reduction in cardiovascular events in SELECT. Both are peptides, both are injected, and both sit in a different evidentiary and legal universe from anything in the two sections above, with more than fifteen phase 3 trials behind semaglutide and over a decade of surveillance behind liraglutide.
Khloé Kardashian has addressed the Ozempic trend publicly; E! News reported her comments on how she feels about it. That is all the record supports. She has not said she uses a GLP-1, she has not said she does not, and we will not read a body shape as a prescription. The class is here for one reason: the same four words, daily peptide injection, can describe a compounded research vial or a fully approved medicine, and that difference is the entire question.
The hair gummies: what a hair growth peptide usually is
OMI Hair Growth Peptides are gummies. That single fact settles most of the questions people bring to them. A gummy is a dietary supplement, regulated under the Dietary Supplement Health and Education Act of 1994: no pre-market approval, no efficacy trial, and structure/function claims such as supports hair growth are permitted provided the standard disclaimer appears and no disease is named. Nothing in that framework requires the company to show the product does what its name suggests.
We could not verify OMI's formula from the sources available to us, and we are not going to guess at it. What we can describe is the category. Hair gummies marketed as peptides are almost always built around hydrolysed collagen, fragments of bovine, porcine or marine collagen broken by enzymes into short chains that survive digestion; biotin, often at many times the daily requirement; and a rotating cast of botanicals and vitamins. The peptide in the name is usually collagen. That is not a sneer; collagen dipeptides genuinely appear in plasma after an oral dose. It is a statement about scale: a gummy delivers a digestion product by mouth, a syringe delivers a designed signal past every barrier the body has, and a testimonial for one says nothing about the other.
Does oral collagen or biotin actually grow hair?
For collagen, the honest answer is that the hair question has barely been asked. The randomised trials that exist measure skin. A 2021 systematic review and meta-analysis pooled nineteen studies of hydrolysed collagen and found improvements in skin hydration and elasticity, with the usual caveats of short durations, small samples and manufacturer funding. We could not find a controlled trial of oral collagen peptides alone with a blinded hair-count or hair-density endpoint. That does not mean collagen does nothing for hair; it means nobody has properly measured it.
Biotin is clearer, in the direction that sells worse. Deficiency does cause hair loss, and correcting it restores the hair. In people who are not deficient, which is nearly everyone on a mixed diet, there is no controlled evidence that supplemental biotin grows hair; a 2017 review of every published case in which biotin helped hair or nails found each involved an underlying condition. Biotin also has a downside hair marketing never mentions: at supplement doses it interferes with common immunoassays, and the FDA warned in 2017 and 2019 that it had produced falsely low troponin results, the test for a heart attack.
So the hair-gummy evidence stack, once the celebrity comes off the label, reads: plausible absorption, modest skin data, no hair data for collagen, deficiency-only data for biotin. Someone who takes one every morning for a year and sees fuller hair may be seeing something real; it is just more likely explained by regression to the mean, below, than by anything inside the gummy.
One word, three categories: gummy peptide, approved peptide, research peptide
The word peptide is doing a great deal of work here. Chemically, a peptide is a short chain of amino acids, so a collagen fragment in a gummy, liraglutide in a prescription pen and BPC-157 in a research vial are all peptides. Pharmacologically and legally they are three different things. The gummy is a food-category product with no required trial. The approved drug has a label, phase 3 trials, adverse event reporting, a quality system and a prescriber. The research peptide becomes an unapproved new drug the moment anyone injects it, and its label means the seller makes no promise that the contents are sterile, correctly identified or accurately quantified.
Marketing exploits the shared word in both directions. The gummy borrows the glamour of the injectable; the injectable borrows the harmless image of the gummy. When Khloé Kardashian says she cannot see her life without peptides, and means both a morning gummy and a daily shot, she is speaking the way the market speaks. The reader's job is to refuse to let the word carry evidence from one category into another.
What Kris Jenner said, and the stake she disclosed
Khloé's mother has been the more specific of the two. In an Instagram Story reported by HOLA! on 5 September 2026, Kris Jenner said she takes OMI Hair Growth Peptides gummies, "two a day, and it pretty much changed my life", and added: "I became a stakeholder because I believe in it." That is a disclosed financial interest in the company whose product both women promote, and it belongs beside every quote about the gummies. Jenner's stake is on the record; Khloé Kardashian's own commercial relationship with OMI, if any, is not established in our sources, and we do not assert one.
Jenner has also spoken about injections. On Khloé's podcast, Khloé in Wonder Land, which launched in January 2025, she said that "a peptide injection was really great for me". Like her daughter, she did not name it. Two members of one family praising an unnamed peptide injection feels like corroboration and is not: the same clinic, the same adviser and the same enthusiasm can produce identical language about a product that has never been tested.
None of this makes either woman insincere. A stake disclosed is a stake handled correctly, and I believe in it is presumably true. It changes what the statement is evidence of: a testimonial from a stakeholder shows the stakeholder is satisfied. It is not evidence about hair.
How to read a celebrity peptide testimonial
Three tools do most of the work. The first is to name the evidence type. It changed my life is a testimonial: one person, no control, no blinding, an outcome chosen after the fact, reported by someone whose livelihood depends on looking well. Testimonials are where hypotheses come from, and medicine's history is full of treatments that had thousands of them and failed the first controlled trial. The second is regression to the mean. Hair shedding cycles, with a documented seasonal peak in late summer, and spikes after illness, childbirth, rapid weight loss and stress. People start a supplement when shedding is worst and credit it when shedding returns to normal, as it would have anyway.
The third is undisclosed adjuncts. The interview that gave us the peptide quote was, by ELLE's own framing, a candid conversation about fillers as well, and Khloé Kardashian has been unusually open about cosmetic work, which is to her credit. It also means any change attributed to peptides sits inside a stack of other procedures, professionals, lighting and retouching that no reader can separate out. When someone with access to the best dermatologists, trainers and surgeons in Los Angeles says one daily injection changed everything, the arithmetic of attribution runs against the injection.
Once the famous name comes off the vial, what remains is this: a secretagogue pair with phase 1 pharmacology and no outcome trial; a healing peptide with hundreds of rat studies and no human RCT; a copper peptide with topical data and none for injection; two approved GLP-1s with the best evidence in the field; and a gummy whose likely ingredients have modest skin data and no hair data. Khloé Kardashian's enthusiasm is real, warmly expressed and, on the evidence, unverifiable. That is not an accusation. It is what a testimonial is.